Vestal Point Capital, LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Vestal Point Capital, LP reported 90 stock positions worth $3.6 billion. Its top holding was Revolution Medicines (RVMD) at 6.5% of the portfolio, followed by Biomarin Pharmaceutical (BMRN, 5.6%) and Abivax SA-ADR (ABVX, 4.7%). Compared with Q4 2025, it opened 37 new positions, sold out of 22, added to 33 and reduced 14. The biggest buy was Revolution Medicines (RVMD, shares +705%) and the biggest sale an exit from Arcellx (ACLX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001974915
- Portfolio Value
- $3.6B (Q1 2026)
- SEC Filing
- 0001974915-26-000004 ↗ filed May 15, 2026
Holdings Value
Holdings 90 stocks · $3.6B
| RVMD Revolution Medicines Inc. | 6.46% | 2,375,000 | $231.0M | Add +705.1% |
| BMRN Biomarin Pharmaceutical Inc. | 5.65% | 3,575,000 | $202.0M | Add +19.2% |
| ABVX Abivax SA-ADR | 4.67% | 1,500,000 | $167.0M | Reduce -21.1% |
| NBIX Neurocrine Biosciences Inc. | 4.60% | 1,250,000 | $164.7M | New |
| ARWR Arrowhead Pharmaceuticals Inc. | 3.99% | 2,275,000 | $142.6M | Add +152.8% |
| ELVN Enliven Therapeutics Inc. | 3.56% | 3,250,000 | $127.4M | Reduce -15.1% |
| RGEN Repligen Corp. | 3.05% | 925,000 | $109.0M | Add +1014.5% |
| BCAX Bicara Therapeutics Inc. | 3.02% | 5,425,000 | $107.9M | Add +51.8% |
| NRIX Nurix Therapeutics Inc. | 2.82% | 6,500,000 | $100.8M | Add +38.6% |
| APGE Apogee Therapeutics Inc. | 2.59% | 1,100,000 | $92.6M | Add +100.0% |
| ASND Ascendis Pharma A/S | 2.40% | 375,000 | $85.8M | Add +114.3% |
| IMCR Immunocore Holdings PLC-ADR | 2.33% | 2,766,868 | $83.4M | Add +373.0% |
| TSHA Taysha Gene Therapies Inc. | 2.25% | 18,000,000 | $80.5M | Add +30.9% |
| DYN Dyne Therapeutics Inc. | 2.03% | 4,000,000 | $72.5M | Add +3233.3% |
| SNY Sanofi-ADR | 1.89% | 1,400,000 | $67.5M | New |
| BCRX Biocryst Pharmaceuticals Inc. | 1.87% | 7,025,000 | $66.9M | Add +212.2% |
| SRRK Scholar Rock Holding Corp. | 1.82% | 1,324,422 | $65.1M | Add +89.2% |
| IMTX Immatics NV | 1.70% | 6,175,000 | $60.8M | Add +0.8% |
| BMY Bristol-Myers Squibb Co. | 1.70% | 1,000,000 | $60.6M | Add +300.0% |
| ALC Alcon Inc. filed as ALCON AG | 1.69% | 800,000 | $60.3M | Reduce -27.6% |
| GLUE Monte Rosa Therapeutics Inc. | 1.66% | 3,603,465 | $59.3M | Add +365.0% |
| VERA Vera Therapeutics Inc. | 1.54% | 1,368,159 | $55.0M | Add +148.8% |
| TERN Terns Pharmaceuticals Inc. | 1.47% | 1,000,000 | $52.7M | Reduce -77.8% |
| GMED Globus Medical Inc. Class A | 1.47% | 610,520 | $52.6M | Reduce -52.1% |
| BSX Boston Scientific Corp. | 1.40% | 800,000 | $50.2M | New |
| NUVL Nuvalent Inc. Class A | 1.38% | 481,715 | $49.4M | Add +947.2% |
| COGT Cogent Biosciences Inc. | 1.32% | 1,230,888 | $47.4M | New |
| ANRO Alto Neuroscience Inc. | 1.30% | 2,064,075 | $46.4M | Reduce -16.9% |
| RAPP Rapport Therapeutics Inc. | 1.26% | 1,436,229 | $44.9M | Add +29.4% |
| IRON Disc Medicine Inc. | 1.25% | 700,000 | $44.8M | Reduce -4.8% |
| UTHR United Therapeutics Corp. | 1.24% | 75,000 | $44.5M | New |
| CLDX Celldex Therapeutics Inc. | 1.09% | 1,224,165 | $38.8M | Add +5.1% |
| KALV Kalvista Pharmaceuticals Inc. | 1.04% | 1,850,000 | $37.2M | Reduce -2.1% |
| XENE Xenon Pharmaceuticals Inc. | 1.04% | 639,900 | $37.2M | Add +6.7% |
| SLDB Solid Biosciences Inc. | 1.01% | 5,000,000 | $36.0M | Reduce -14.0% |
| DRUG Bright Minds Biosciences Inc. | 1.00% | 492,319 | $35.9M | New |
| PTGX Protagonist Therapeutics Inc. | 0.96% | 326,159 | $34.4M | New |
| DNLI Denali Therapeutics Inc. | 0.95% | 1,773,326 | $34.0M | Add +281.4% |
| REGN Regeneron Pharmaceuticals | 0.86% | 40,000 | $30.9M | New |
| WAT Waters Corp. | 0.83% | 100,000 | $29.8M | New |
| VKTX Viking Therapeutics Inc. | 0.83% | 914,147 | $29.7M | New |
| INSP Inspire Medical Systems Inc. | 0.78% | 539,269 | $27.8M | New |
| CBIO Crescent Biopharma Inc. | 0.77% | 1,500,000 | $27.6M | No change |
| TRVI Trevi Therapeutics Inc. | 0.72% | 2,166,504 | $25.8M | New |
| LXEO Lexeo Therapeutics Inc. | 0.72% | 4,475,000 | $25.7M | No change |
| SLNO Soleno Therapeutics Inc. | 0.68% | 730,000 | $24.4M | New |
| BBNX Beta Bionics Inc. | 0.62% | 2,211,518 | $22.2M | Add +268.6% |
| NKTR Nektar Therapeutics | 0.57% | 285,000 | $20.5M | New |
| CYTK Cytokinetics Inc. | 0.55% | 300,000 | $19.8M | New |
| AZN Astrazeneca PLC | 0.55% | 100,000 | $19.7M | New |
| WST West Pharmaceutical Services | 0.53% | 75,000 | $18.8M | New |
| GEHC GE Healthcare Technology | 0.50% | 250,000 | $17.8M | New |
| SGP Spyglass Pharma Inc. | 0.48% | 666,760 | $17.3M | New |
| ZBH Zimmer Biomet Holdings Inc. | 0.48% | 190,000 | $17.2M | Add +26.7% |
| MDGL Madrigal Pharmaceuticals Inc. | 0.46% | 31,468 | $16.5M | New |
| WGS Genedx Holdings Corp. | 0.45% | 250,000 | $16.1M | New |
| DMRA Damora Therapeutics Inc. | 0.43% | 600,000 | $15.5M | New |
| AGIO Agios Pharmaceuticals Inc. | 0.43% | 450,000 | $15.2M | Add +38.5% |
| ENGN Engene Holdings Inc. | 0.41% | 2,165,000 | $14.7M | Add +105.2% |
| SVRA Savara Inc. | 0.40% | 2,600,052 | $14.2M | Add +61.9% |
| TARS Tarsus Pharmaceuticals Inc. | 0.39% | 200,000 | $14.0M | New |
| VYGR Voyager Therapeutics Inc. | 0.32% | 3,002,936 | $11.6M | Add +103.6% |
| PODD Insulet Corp. | 0.30% | 50,601 | $10.6M | New |
| TECX Tectonic Therapeutic Inc. | 0.28% | 328,000 | $10.1M | No change |
| SRZN Surrozen Inc. | 0.28% | 338,611 | $9.9M | New |
| ARVN Arvinas Inc. | 0.27% | 905,465 | $9.6M | New |
| MPLT Maplight Therapeutics Inc. | 0.24% | 420,000 | $8.5M | Add +9.1% |
| FULC Fulcrum Therapeutics Inc. | 0.24% | 1,100,000 | $8.4M | Add +15.8% |
| OKUR Onkure Therapeutics Inc. Class A | 0.21% | 1,839,819 | $7.6M | Add +189.7% |
| MYGN Myriad Genetics Inc. | 0.21% | 1,648,000 | $7.4M | Add +34.8% |
| OLMA Olema Pharmaceuticals Inc. | 0.18% | 428,551 | $6.4M | Reduce -74.0% |
| AVR Anteris Technologies Global | 0.18% | 1,144,780 | $6.4M | New |
| QURE Uniqure NV | 0.16% | 358,996 | $5.9M | New |
| CADL Candel Therapeutics Inc. | 0.15% | 1,125,000 | $5.5M | New |
| PALI Palisade Bio Inc. | 0.12% | 2,500,000 | $4.4M | New |
| VCYT Veracyte Inc. | 0.12% | 130,687 | $4.2M | New |
| ZBIO Zenas Biopharma Inc. | 0.11% | 200,000 | $3.9M | New |
| GERN Geron Corp. | 0.11% | 2,540,000 | $3.8M | Reduce -77.6% |
| MNPR Monopar Therapeutics Inc. | 0.10% | 65,418 | $3.6M | New |
| ZURA Zura Bio Ltd. | 0.09% | 511,000 | $3.0M | New |
| NVCR Novocure Ltd. | 0.08% | 250,000 | $2.7M | Reduce -52.4% |
| NYXH Nyxoah SA | 0.07% | 868,661 | $2.5M | Reduce -21.5% |
| URGN Urogen Pharma Ltd. | 0.07% | 139,079 | $2.5M | New |
| PASG Passage Bio Inc. | 0.07% | 305,000 | $2.4M | No change |
| TYRA Tyra Biosciences Inc. | 0.06% | 54,000 | $2.1M | Reduce -97.8% |
| RGNX Regenxbio Inc. | 0.03% | 108,525 | $909K | Add +219.2% |
| TENX Tenax Therapeutics Inc. | 0.02% | 53,439 | $854K | No change |
| MGNX Macrogenics Inc. | 0.02% | 280,000 | $809K | No change |
| ABSI Absci Corp. | 0.02% | 232,219 | $697K | New |
| APRE Aprea Therapeutics Inc. | 0.01% | 350,000 | $267K | New |
Portfolio Sells Q4 2025 → Q1 2026
| ACLX Arcellx Inc. | Sold out | 0.00% | −7.00 |
| TERN Terns Pharmaceuticals Inc. | Reduce -77.8% | 1.47% | −5.19 |
| ABVX Abivax SA-ADR | Reduce -21.1% | 4.67% | −4.73 |
| DXCM Dexcom Inc. | Sold out | 0.00% | −3.10 |
| MRK Merck & Co. Inc. | Sold out | 0.00% | −2.99 |
| ABT Abbott Laboratories | Sold out | 0.00% | −2.76 |
| GMED Globus Medical Inc. Class A | Reduce -52.1% | 1.47% | −2.61 |
| TYRA Tyra Biosciences Inc. | Reduce -97.8% | 0.06% | −2.28 |
| JAZZ Jazz Pharmaceuticals PLC | Sold out | 0.00% | −1.81 |
| DAWN Day One Biopharmaceuticals I | Sold out | 0.00% | −1.78 |
| ALC Alcon Inc. | Reduce -27.6% | 1.69% | −1.51 |
| AXSM Axsome Therapeutics Inc. | Sold out | 0.00% | −1.41 |
| OLMA Olema Pharmaceuticals Inc. | Reduce -74.0% | 0.18% | −1.33 |
| IRON Disc Medicine Inc. | Reduce -4.8% | 1.25% | −0.89 |
| LNTH Lantheus Holdings Inc. | Sold out | 0.00% | −0.88 |
| ZYME Zymeworks Inc. | Sold out | 0.00% | −0.84 |
| UPB Upstream Bio Inc. | Sold out | 0.00% | −0.72 |
| PEN Penumbra Inc. | Sold out | 0.00% | −0.57 |
| GERN Geron Corp. | Reduce -77.6% | 0.11% | −0.44 |
| ANRO Alto Neuroscience Inc. | Reduce -16.9% | 1.30% | −0.33 |
| MIND MEDICINE MINDMED INC | Sold out | 0.00% | −0.31 |
| GILD Gilead Sciences Inc. | Sold out | 0.00% | −0.23 |
| DBVT DBV Technologies SA-Spon ADR | Sold out | 0.00% | −0.21 |
| SLDB Solid Biosciences Inc. | Reduce -14.0% | 1.01% | −0.20 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −0.19 |
| NVCR Novocure Ltd. | Reduce -52.4% | 0.08% | −0.17 |
| LENZ Lenz Therapeutics Inc. | Sold out | 0.00% | −0.16 |
| RZLT Rezolute Inc. | Sold out | 0.00% | −0.15 |
| NYXH Nyxoah SA | Reduce -21.5% | 0.07% | −0.12 |
| STRO Sutro Biopharma Inc. | Sold out | 0.00% | −0.10 |
| GPCR Structure Therapeutics Inc. | Sold out | 0.00% | −0.09 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -2.1% | 1.04% | −0.08 |
| BDTX Black Diamond Therapeutics I | Sold out | 0.00% | −0.08 |
| FATE Fate Therapeutics Inc. | Sold out | 0.00% | −0.06 |
| ALEC Alector Inc. | Sold out | 0.00% | −0.04 |
| ELVN Enliven Therapeutics Inc. | Reduce -15.1% | 3.56% | +1.40 |
Portfolio Buys Q4 2025 → Q1 2026
| RVMD Revolution Medicines Inc. | Add +705.1% | 6.46% | +5.60 |
| NBIX Neurocrine Biosciences Inc. | New | 4.60% | +4.60 |
| RGEN Repligen Corp. | Add +1014.5% | 3.05% | +2.55 |
| DYN Dyne Therapeutics Inc. | Add +3233.3% | 2.03% | +1.94 |
| SNY Sanofi-ADR | New | 1.89% | +1.89 |
| ARWR Arrowhead Pharmaceuticals Inc. | Add +152.8% | 3.99% | +1.80 |
| IMCR Immunocore Holdings PLC-ADR | Add +373.0% | 2.33% | +1.59 |
| BSX Boston Scientific Corp. | New | 1.40% | +1.40 |
| COGT Cogent Biosciences Inc. | New | 1.32% | +1.32 |
| UTHR United Therapeutics Corp. | New | 1.24% | +1.24 |
| BCRX Biocryst Pharmaceuticals Inc. | Add +212.2% | 1.87% | +1.23 |
| GLUE Monte Rosa Therapeutics Inc. | Add +365.0% | 1.66% | +1.21 |
| NUVL Nuvalent Inc. Class A | Add +947.2% | 1.38% | +1.21 |
| BMY Bristol-Myers Squibb Co. | Add +300.0% | 1.70% | +1.20 |
| APGE Apogee Therapeutics Inc. | Add +100.0% | 2.59% | +1.07 |
| ASND Ascendis Pharma A/S | Add +114.3% | 2.40% | +1.03 |
| DRUG Bright Minds Biosciences Inc. | New | 1.00% | +1.00 |
| PTGX Protagonist Therapeutics Inc. | New | 0.96% | +0.96 |
| REGN Regeneron Pharmaceuticals | New | 0.86% | +0.86 |
| WAT Waters Corp. | New | 0.83% | +0.83 |
| VKTX Viking Therapeutics Inc. | New | 0.83% | +0.83 |
| BCAX Bicara Therapeutics Inc. | Add +51.8% | 3.02% | +0.81 |
| INSP Inspire Medical Systems Inc. | New | 0.78% | +0.78 |
| TRVI Trevi Therapeutics Inc. | New | 0.72% | +0.72 |
| SRRK Scholar Rock Holding Corp. | Add +89.2% | 1.82% | +0.69 |
| SLNO Soleno Therapeutics Inc. | New | 0.68% | +0.68 |
| DNLI Denali Therapeutics Inc. | Add +281.4% | 0.95% | +0.67 |
| NKTR Nektar Therapeutics | New | 0.57% | +0.57 |
| CYTK Cytokinetics Inc. | New | 0.55% | +0.55 |
| AZN Astrazeneca PLC | New | 0.55% | +0.55 |
| WST West Pharmaceutical Services | New | 0.53% | +0.53 |
| VERA Vera Therapeutics Inc. | Add +148.8% | 1.54% | +0.52 |
| GEHC GE Healthcare Technology | New | 0.50% | +0.50 |
| SGP Spyglass Pharma Inc. | New | 0.48% | +0.48 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 0.46% | +0.46 |
| WGS Genedx Holdings Corp. | New | 0.45% | +0.45 |
| DMRA Damora Therapeutics Inc. | New | 0.43% | +0.43 |
| TARS Tarsus Pharmaceuticals Inc. | New | 0.39% | +0.39 |
| PODD Insulet Corp. | New | 0.30% | +0.30 |
| SRZN Surrozen Inc. | New | 0.28% | +0.28 |
| ARVN Arvinas Inc. | New | 0.27% | +0.27 |
| AVR Anteris Technologies Global | New | 0.18% | +0.18 |
| QURE Uniqure NV | New | 0.16% | +0.16 |
| CADL Candel Therapeutics Inc. | New | 0.15% | +0.15 |
| OKUR Onkure Therapeutics Inc. Class A | Add +189.7% | 0.21% | +0.15 |
| PALI Palisade Bio Inc. | New | 0.12% | +0.12 |
| VCYT Veracyte Inc. | New | 0.12% | +0.12 |
| VYGR Voyager Therapeutics Inc. | Add +103.6% | 0.32% | +0.11 |
| ZBIO Zenas Biopharma Inc. | New | 0.11% | +0.11 |
| AGIO Agios Pharmaceuticals Inc. | Add +38.5% | 0.43% | +0.10 |
Options Activity Q4 2025 → Q1 2026
| QQQ Invesco QQQ Trust Series 1 | put | Sold out | 350,000 | $215.0Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $4.3B | BMRN, NBIX, ABVX, UTHR, ELVN |
| Q1 2026 | 90 | $3.6B | RVMD, BMRN, ABVX, NBIX, ARWR |
| Q4 2025 | 75 | $2.7B | ABVX, ACLX, TERN, BMRN, GMED |
| Q3 2025 | 80 | $2.2B | ASND, ACLX, NUVL, ABVX, ALC |
| Q2 2025 | 72 | $1.9B | ACLX, JAZZ, CYTK, NUVL, VERA |
| Q1 2025 | 63 | $1.4B | ACLX, CYTK, INSM, NUVL, VERA |
| Q4 2024 | 73 | $1.7B | JAZZ, CYTK, MRK, ASND, RARE |
| Q3 2024 | 67 | $1.3B | INSM, JAZZ, CYTK, NARI, ACLX |
| Q2 2024 | 60 | $1.3B | JAZZ, CYTK, ASND, RARE, GMED |
| Q1 2024 | 58 | $1.2B | CYTK, JAZZ, NBIX, ASND, GMED |